Table 1 Mendelian randomisation inverse variance weighted and sensitivity analysis estimates for the effect per unit decrease in exposure-mediated natural log transformed C-reactive protein (CRP) levels on risk of the positive (rheumatoid arthritis) and negative (osteoarthritis) controls.
From: The effect of immunomodulatory drugs on aortic stenosis: a Mendelian randomisation analysis
Proxied drug | MR analysis method | Rheumatoid arthritis Odds ratio (95% CI) | Osteoarthritis Odds ratio (95% CI) |
|---|---|---|---|
Tocilizumab (IL6R) | IVW | 0.57 (0.39–0.82) | 0.82 (0.64–1.04) |
Weighted-median | 0.44 (0.32–0.61) | 0.83 (0.60–1.15) | |
Weighted-mode | 0.51 (0.38–0.68) | 0.81 (0.60–1.09) | |
MR-Egger | 0.28 (0.10–0.74) | 0.91 (0.47–1.75) | |
MR-PRESSO | 0.53 (0.29–0.95) | NA | |
MR-RAPS | 0.51 (0.28–0.93) | 0.82 (0.64–1.04) | |
Canakinumab (IL1β) | IVW | 0.49 (0.30–0.79) | 1.23 (0.78–1.95) |
Weighted-median | 0.43 (0.23–0.81) | 1.30 (0.72–2.35) | |
Weighted-mode | 0.24 (0.11–0.53) | 1.26 (0.70–2.29) | |
MR-Egger | 0.13 (0.03–0.52) | 1.42 (0.35–5.72) | |
MR-PRESSO | NA | NA | |
MR-RAPS | 0.47 (0.29–0.75) | 1.24 (0.78–1.96) | |
Colchicine (β-tubulin gene family) | Wald Ratio | 0.72 (0.02–21.51) | 1.72 (0.10–28.08) |
Overall CRP | IVW | 0.93 (0.87–0.98) | 0.95 (0.89–1.00) |
Weighted-median | 0.96 (0.87–1.06) | 0.96 (0.87–1.07) | |
Weighted-mode | 0.95 (0.86–1.04) | 0.98 (0.88–1.08) | |
MR-Egger | 0.91 (0.88–1.00) | 1.13 (1.03–1.23) | |
MR-PRESSO | 0.96 (0.91–1.02) | 0.95 (0.90–1.00) | |
MR-RAPS | 0.94 (0.88–1.00) | 0.96 (0.90–1.02) |
